Posted by Michael Wonder on 25 Jul 2022
BridgeBio Pharma and Sentynl Therapeutics receive positive CHMP opinion for Nulibry (fosdenopterin) for the treatment of MoCD type A
25 July 2022 - CHMP recommendation for approval of Nulibry in the European Union for the treatment of patients with molybdenum cofactor deficiency type A is based on the efficacy and safety data collected to date compared to data from a natural history study.
BridgeBio Pharma and Sentynl Therapeutics today announced that the CHMP of the EMA has recommended that the European Commission authorise marketing under exceptional circumstances for Nulibry (fosdenopterin) for Injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency type A.
